Studies have shown that cancer cells treated with epidermal growth factor receptor inhibitors often exhibit increased sensitivity to anticancer drugs, further underscoring the pivotal role of FGF/FGFR signaling in cancer stem cell regulation and highlighting its potential as a therapeutic target. Here, EGFR is linked to cancer.